Relmada Therapeutics (RLMD) Change in Acquisitions & Divestments (2020 - 2026)

Relmada Therapeutics (RLMD) has reported Change in Acquisitions & Divestments for 7 consecutive years, with $14.3 million the latest figure, recorded in Q1 2026.

• In Q1 2026, Change in Acquisitions & Divestments fell 9.83% year-over-year to $14.3 million; the TTM figure through Mar 2026 stood at $34.1 million (down 45.31% YoY), while the FY2025 annual figure was $35.7 million, down 43.92% from the prior year.
• Change in Acquisitions & Divestments improved to $14.3 million in Q1 2026 per RLMD's latest filing, from $5.9 million in the prior quarter.
• Across five years, Change in Acquisitions & Divestments topped out at $74.8 million in Q1 2023 and bottomed at $5.9 million in Q4 2025.
• Historically, Change in Acquisitions & Divestments has averaged $18.9 million across 5 years, with a median of $15.3 million in 2024.
• Annual changes were most pronounced in 2022 — Change in Acquisitions & Divestments plunged 86.53% — and 2023, when it jumped 517.79%.
• Relmada Therapeutics' Change in Acquisitions & Divestments stood at $6.6 million in 2022, then surged by 517.79% to $41.1 million in 2023, then tumbled by 70.77% to $12.0 million in 2024, then plunged by 51.2% to $5.9 million in 2025, then soared by 144.04% to $14.3 million in 2026.
• Business Quant data shows RLMD's Change in Acquisitions & Divestments at $14.3 million in Q1 2026, $5.9 million in Q4 2025, and $7.0 million in Q3 2025.